1. Vertex Pharmaceuticals press releases available at: http://investors.vrtx.com/releaseDetail.cfm?releaseid=325650, 2008 and http://investors.vrtx.com/releasedetail.cfm?ReleaseID=276543, 2007. Last accessed July 22, 2010.
2. The clinical evaluation of QT/QTc prolongation and pro-arrhythmic potential for non-antiarrhythmic drugs: E14;International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use,2005
3. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes;Darpo;Eur Heart J Suppl,2003
4. QT as a safety biomarker in drug development;Whellan;Clin Pharmacol Ther,2009
5. Potential for QT prolongation and pro-arrhythmia by non–anti-arrhythmic drugs: clinical and regulatory implications report on a Policy Conference of the European Society of Cardiology;HaverKamp;Cardiovasc Res,2000